Hyperphenylalaninemia due to dehydratase deficiency is a genetically determined disorder of amino acid metabolism. This disease is characterized by elevated plasma phenylalanine levels, which can lead to severe neurological and developmental impairment. Hyperphenylalaninemia causes a variety of clinical manifestations, including mental retardation, seizures, and various motor disorders. If not adequately diagnosed and treated, this condition can significantly affect the patient's quality of life and social adaptation.
History of the disease and interesting historical facts
Hyperphenylalaninemia was first described in 1934 by Swiss physician Frederick Landerer. He observed a pathological condition associated with high serum phenylalanine levels in a patient, which later became the basis for the scientific definition of the disease. However, the clinical significance of hyperphenylalaninemia only became apparent in 1953, when a link was established between the condition and serious neurological disorders. In the 1960s, with the development of laboratory diagnostic methods, a large-scale screening program was launched, which made it possible to detect the disease at an early stage and adjust the diet of patients, thereby significantly reducing the level of phenylalanine in the blood.
Epidemiology
Epidemiological studies have shown that the incidence of hyperphenylalaninemia varies by geographic region and ethnic group. Globally, the incidence is approximately 1 in 100,000 live births. In some populations, such as those of northern European descent, the incidence may be as high as 1 in 10,000. Effective neonatal screening programs have reduced the incidence and improved patient outcomes by allowing treatment to be initiated before clinical symptoms appear.
Genetic predisposition to this disease
Hyperphenylalaninemia is a hereditary disease that is transmitted in an autosomal recessive manner. The main gene responsible for this condition is the PAH gene, located on chromosome 12. Deficiency of the enzyme phenylalanine hydroxylase, produced by this gene, leads to the accumulation of phenylalanine in the body. To date, more than 900 mutations in the PAH gene are known, which lead to varying degrees of severity of the disease, ranging from mild forms to extremely severe, life-threatening conditions. Such genetic variability makes the diagnosis and treatment of hyperphenylalaninemia particularly difficult and requires an individual approach.
Risk factors for the development of this disease
Although the disease is primarily caused by genetic factors, certain external circumstances may increase the risk of developing or worsening the condition. Risk factors include:
- Hereditary predisposition (presence of cases of the disease in the family).
- Cases of autosomal recessive diseases in the family.
- Disorders in the metabolism of tyrosine and other amino acids.
- Problems with dietary compliance in individuals with a known diagnosis of hyperphenylalaninemia.
Diagnosis of this disease
The main symptoms of hyperphenylalaninemia include neurological disorders, psychomotor retardation, seizures, and behavioral disturbances. Laboratory tests such as serum phenylalanine levels are key to diagnosis. It has been shown that high phenylalanine levels in newborns can be detected by neonatal screening, allowing treatment to begin before clinical manifestations occur.
Additional diagnostic tests may include radiological studies such as MRI of the brain to evaluate its structure and identify possible abnormalities. The differential diagnosis of hyperphenylalaninemia should be made with other metabolic disorders associated with amino acid metabolism, such as tyrosinemia and keratosis.
Treatment
Treatment of hyperphenylalaninemia is aimed at reducing the level of phenylalanine in the blood and includes both general methods and pharmacological therapy. The main approaches include:
- A strict diet with restrictions on foods rich in phenylalanine (meat, fish, eggs, dairy products).
- Special protein substitutes and amino acid blends containing low levels of phenylalanine.
- Pharmacological treatment using drugs that promote phenylalanine metabolism (eg, methyltetrahydropterin).
- Genetic therapy and exivcade (possible directions for severe cases).
List of medications used to treat this disease
The list of medications used in the treatment of hyperphenylalaninemia includes:
- Tetrahydrobiopterin (BH4).
- Saquina (leads to a decrease in phenylalanine levels).
- Special amino acid preparations.
Disease monitoring
Regular monitoring of the condition of patients with hyperphenylalaninemia includes control of phenylalanine levels in the blood, which allows timely adjustment of diet and therapy. The prognosis with early treatment is favorable in most cases, but failure to follow recommendations may result in severe neurological complications, including mental retardation and growth retardation.
Age-related features of the disease
Hyperphenylalaninemia may present differently depending on the age of the patient. In neonates and infants, symptoms may be subtle, while in older children and adults, severe neurological impairment may occur. In adolescents, additional problems related to psychosocial aspects and dietary compliance may occur, which require special attention from physicians and parents.
Questions and Answers
- What is hyperphenylalaninemia? This is a genetic disorder associated with a disorder of phenylalanine metabolism, causing its accumulation in the body.
- What are the symptoms of hyperphenylalaninemia? The main symptoms include developmental delay, seizures, physical impairments and behavioral disorders.
- How to diagnose hyperphenylalaninemia? Diagnosis is made using laboratory analysis of blood phenylalanine levels and clinical assessment of the neurological status.
- Should I follow a diet for hyperphenylalaninemia? Yes, a strict diet that limits phenylalanine is the mainstay of therapy to control the amino acid levels in the body.
- What is the outlook for treatment of hyperphenylalaninemia? With early initiation of treatment and adherence to dietary recommendations, the prognosis is usually favorable, but requires constant monitoring.
Dr. Oleg Korzhikov notes that it is important to seek medical help at the slightest sign of developmental disorders in newborns. “Early detection of hyperphenylalaninemia makes it possible to significantly improve the patient’s quality of life,” he says. Parents’ questions about nutrition, the need for screening tests, and subsequent health monitoring should be discussed with a medical professional to ensure proper care and support for the patient throughout life.
